AVII completes Avicine Phase II in pancreatic cancer

AVI BioPharma (AVII) completed enrollment of 50 patients in a U.S. Phase II of Avicine, an anti-human chorionic gonadotropin synthetic peptide vaccine to treat pancreatic cancer. The trial will assess...